Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,263 stopped studies mapped to Lung Carcinoma and descendants · 91% state a reason
Over the 1,263 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05161533 | Hypofractionated Radiation Therapy After Durvalumab and Chemotherapy for the Treatment of… | Phase 2 | withdrawn | Dec 17, 2021 | University of Washington | Closed per SRC Low Accrual Policy. Study closed prior to any participants enrolled. | Enrollment / accrual |
| NCT05180422 | A Phase I/II Study of AMG 510 in Combination With MVASI in Patients With Advanced,… | Phase 1 / Phase 2 | withdrawn | Jan 6, 2022 | Criterium, Inc. | Lack of enrollment | Enrollment / accrual |
| NCT05863819 | A Real World Study of Mobocertinib in Adults With Lung Cancer in China (MEANING)(MEANING-20) | — | withdrawn | May 18, 2023 | Takeda | Business reason, unrelated to product safety | Safety / toxicity |
| NCT02899728 | Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small… | Phase 2 | terminated | Sep 14, 2016 | National Cancer Institute (NCI) | Inadequate accrual rate | Enrollment / accrual |
| NCT03366103 | Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and… | Phase 1 / Phase 2 | terminated | Dec 8, 2017 | National Cancer Institute (NCI) | Drug supply issues | Drug supply |
| NCT05414123 | A Therapy Treatment Response Trial in Patients With Leptomeningeal Metastases ((LM) Using…(FORESEE) | — | terminated | Jun 10, 2022 | Biocept, Inc. | The sponsor can no longer financially support the trial. | Funding |
| NCT03951012 | Use Peripheral Blood Proteomics to Predict the Treatment Response and Toxicities in NSCLC… | — | terminated | May 15, 2019 | Muhammad Furqan | low enrollment and remaining oncologist workload | Enrollment / accrual |
| NCT04040244 | Exhaled Breath Analysis to Predict Risk of Symptomatic Pneumonitis | N/A | terminated | Jul 31, 2019 | Wake Forest University Health Sciences | The PI is requesting this study to be closed due to the departure of the Co-PI who is an integral… | Other (stated, no rule matched) |
| NCT04082988 | Early Response Evaluation in NSCLC Patients Treated With Immunotherapy | N/A | terminated | Sep 10, 2019 | The Netherlands Cancer Institute | The study has been closed due to slow enrollment. | Enrollment / accrual |
| NCT04989283 | Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy… | Phase 2 | withdrawn | Aug 4, 2021 | National Cancer Institute (NCI) | Due to no accrual | Enrollment / accrual |
| NCT02831933 | Trial of Radiation and Gene Therapy Before Nivolumab for Metastatic Non-Small Cell Lung…(ENSIGN) | Phase 2 | terminated | Jul 13, 2016 | Eric Bernicker, MD | Lack of funding | Funding |
| NCT04106167 | Long-term, Non-interventional, Observational Study Following Treatment With Fate… | — | terminated | Sep 26, 2019 | Fate Therapeutics | This study was terminated by the Sponsor. | Other (stated, no rule matched) |
| NCT05395052 | FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors | Phase 1 | terminated | May 27, 2022 | Fate Therapeutics | This study was terminated by the Sponsor. | Other (stated, no rule matched) |
| NCT03425006 | Pembrolizumab and Itacitinib (INCB039110) for Non-Small Cell Lung Cancer | Phase 2 | terminated | Feb 7, 2018 | University of Pennsylvania | Administrative reasons | Other (stated, no rule matched) |
| NCT05045404 | Poziotinib and Ramucirumab for the Treatment of EGFR Exon 20 Mutant Stage IV Non-small… | Phase 2 | withdrawn | Sep 16, 2021 | M.D. Anderson Cancer Center | Study closed due to funding, 0 patient accrual. | Enrollment / accrual |
| NCT05287971 | Standard of Care Lifestyle Support for Stage III NSCLC Patients(PERCUSSION) | — | withdrawn | Mar 18, 2022 | Maastricht Radiation Oncology | Never started | Other (stated, no rule matched) |
| NCT05230888 | Comprehensive Geriatric Assessment in Elderly Non-Small Cell Lung Cancer Patients | — | withdrawn | Feb 9, 2022 | University of Hull | Research personnel not recruited | Enrollment / accrual |
| NCT04422392 | Neoadjuvant PD-1 Antibody Plus Chemotherapy in Resectable Stage IIIA-N2 Non-Small-Cell… | Phase 2 | terminated | Jun 9, 2020 | Shanghai Pulmonary Hospital, Shanghai, China | since the CheckMate816 study is published in NEJM, enrolling patients becomes difficult | Enrollment / accrual |
| NCT03317496 | Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer… | Phase 1 / Phase 2 | terminated | Oct 23, 2017 | Pfizer | The study was terminated since there was no need for further safety or efficacy data to be… | Safety / toxicity |
| NCT03963414 | A Study of Durvalumab Plus Tremelimumab With Chemotherapy in Untreated ES-SCLC | Phase 1 | terminated | May 24, 2019 | University of Nebraska | low accrual | Enrollment / accrual |
| NCT05935774 | OT-101 in Combination With Atezolizumab for the Treatment of Metastatic or Recurrent… | Phase 2 | withdrawn | Jul 7, 2023 | University of Washington | Withdrawn prior to opening to accrual. | Enrollment / accrual |
| NCT05027867 | KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer | Phase 2 | terminated | Aug 30, 2021 | Kartos Therapeutics, Inc. | Unanticipated and extremely high screen failure rate. There was no evidence of safety concerns in… | Safety / toxicity |
| NCT05106335 | A Study to Evaluate Camrelizumab Combined With Famitinib as Subsequent Therapy in… | Phase 3 | terminated | Nov 3, 2021 | Jiangsu HengRui Medicine Co., Ltd. | Sponsor R \& D Strategy Adjustment | Sponsor / business decision |
| NCT04750239 | Safety and Clinical Activity of Nivatrotamab in Relapsed/Recurrent Metastatic Small-cell… | Phase 1 / Phase 2 | terminated | Feb 11, 2021 | Y-mAbs Therapeutics | Study terminated due to business priorities | Sponsor / business decision |
| NCT03417882 | GRN-1201 With Pembrolizumab in Subjects With Metastatic PD-L1+ NSCLC | Phase 2 | terminated | Jan 31, 2018 | BrightPath Biotherapeutics | Recruitment rate too slow | Enrollment / accrual |
| NCT04644315 | A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in…(ALpha-T) | Phase 2 | terminated | Nov 25, 2020 | Hoffmann-La Roche | The data from this study is no longer needed. | Other (stated, no rule matched) |
| NCT04639245 | Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous… | Phase 1 / Phase 2 | terminated | Nov 20, 2020 | Fred Hutchinson Cancer Center | Terminated due to slow accrual. | Enrollment / accrual |
| NCT03576131 | GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors | Phase 1 / Phase 2 | terminated | Jul 3, 2018 | Genmab | Sponsor decision | Sponsor / business decision |
| NCT04971187 | Bintrafusp Alfa With Chemotherapy for Tyrosine Kinase Inhibitor-Resistant EGFR-Mutant… | Phase 2 | terminated | Jul 21, 2021 | M.D. Anderson Cancer Center | PI Request | Other (stated, no rule matched) |
| NCT04424641 | A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid… | Phase 1 / Phase 2 | terminated | Jun 11, 2020 | Genmab | Study was terminated due to MTD was reached | Other (stated, no rule matched) |
| NCT04705025 | Cognitive-Behavioral Stress Management Device for the Treatment of Anxiety and Depressive…(BNT001) | N/A | terminated | Jan 12, 2021 | Jonsson Comprehensive Cancer Center | manufacturer reevaluating Digital cognitive-behavioral stress management (CBSM) device (Attunetm) | Drug supply |
| NCT02710396 | Genetic Predictors of Benefit to Pembrolizumab | Phase 2 | terminated | Mar 16, 2016 | Columbia University | Frontline pembrolizumab approved in NSCLC as monotherapy and in combination with chemotherapy… | Other (stated, no rule matched) |
| NCT05791097 | Study of Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and…(AdvanTIG-306) | Phase 3 | withdrawn | Mar 30, 2023 | Novartis Pharmaceuticals | Business decision, not driven by safety concerns; no new safety signals have been observed in the… | Safety / toxicity |
| NCT02919449 | Dose Escalation Trial of Intra-Tumoral Injection of NIS Measles Virus in Combination With… | Phase 1 | terminated | Sep 29, 2016 | Vyriad, Inc. | Low recruitment | Enrollment / accrual |
| NCT05171062 | Dose Escalation Trial of Bexmarilimab (FP-1305) Plus Pembrolizumab in Non-Small Cell Lung… | Phase 1 | withdrawn | Dec 28, 2021 | The University of Texas Health Science Center at San Antonio | No participants were enrolled, the study was inactivated with the IRB on May 15, 2023. The sponsor… | Enrollment / accrual |
| NCT05400577 | Sotorasib in KRAS G12C Mutated, Resectable, Stage Ib-IIIA NSCLC | Phase 2 | withdrawn | Jun 1, 2022 | Fox Chase Cancer Center | Grantor withdrew support due to slow accrual | Enrollment / accrual |
| NCT03927573 | Study With Bispecific Antibody Engaging T-cells, in Patients With Progressive Cancer… | Phase 1 | terminated | Apr 25, 2019 | AvenCell Europe GmbH | business decision by sponsor | Sponsor / business decision |
| NCT02584634 | Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In… | Phase 1 / Phase 2 | terminated | Oct 22, 2015 | Pfizer | The study was terminated since there was no need for further safety or efficacy data to be… | Safety / toxicity |
| NCT00750698 | A Phase 2 Exploratory Study of Erlotinib and SNDX-275 in Participants With Non-small Cell… | Phase 2 | terminated | Sep 10, 2008 | Syndax Pharmaceuticals | Due to business reasons, enrollment on the study was halted and the study terminated. The decision… | Safety / toxicity |
| NCT04466917 | A Study of ABP 215 Versus Bevacizumab in Chinese Subjects With Advanced Non-Squamous… | Phase 3 | withdrawn | Jul 10, 2020 | Amgen | Sponsor decision to early terminate the study | Sponsor / business decision |
| NCT03805841 | Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating…(RAIN) | Phase 2 | terminated | Jan 16, 2019 | Rain Oncology Inc | enrollment pause | Enrollment / accrual |
| NCT04381494 | Mobile Devices to Detect Early Pneumonitis in Stage III NSCLC Patients on Durvalumab.(ON TRAX) | Phase 4 | terminated | May 8, 2020 | AstraZeneca | Study was not terminated for any safety concerns; it was stopped early due to inability to enroll… | Safety / toxicity |
| NCT02335944 | Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280… | Phase 1 / Phase 2 | terminated | Jan 12, 2015 | Novartis Pharmaceuticals | Company decision | Sponsor / business decision |
| NCT05153408 | (HARMONY) Study of BLU-701 in EGFR-mutant NSCLC | Phase 1 | terminated | Dec 10, 2021 | Blueprint Medicines Corporation | Lack of efficacy | Efficacy / futility |
| NCT03509584 | Phase I Multicenter Trial Combining Nivolumab, Ipilimumab and Hypo-fractionated… | Phase 1 | terminated | Apr 26, 2018 | Assistance Publique Hopitaux De Marseille | SAFETY | Safety / toxicity |
| NCT05603299 | Establishing Clinical Utility Evidence to Support Coverage and Reimbursement for Venn… | N/A | withdrawn | Nov 2, 2022 | Qure Healthcare, LLC | The study recruited no participants due to a pre-recruitment decision by the sponsor to not… | Enrollment / accrual |
| NCT04372927 | ADMIRAL Trial: Adaptive Mediastinal Radiation With Chemo-Immunotherapy | Phase 2 | terminated | May 4, 2020 | University of Washington | Terminated due to slow accrual | Enrollment / accrual |
| NCT05411679 | EP0057 in Combination With Olaparib in Relapsed Advanced Gastric Cancer and Small Cell… | Phase 2 | withdrawn | Jun 9, 2022 | Ellipses Pharma | Futility analysis decision to terminate EP0057 compound and all Ellipses sponsored studies… | Efficacy / futility |
| NCT03827850 | FGFR Inhibitor in FGFR Dysregulated Cancer(FIND) | Phase 2 | terminated | Feb 4, 2019 | Lung Cancer Group Cologne | Study-related difficulties faced with patient enrolment, no safety-related reasons | Safety / toxicity |
| NCT04699968 | A Trial of SHR-1701 With or Without Famitinib in Patients With Advanced or Metastatic… | Phase 2 | withdrawn | Jan 7, 2021 | Jiangsu HengRui Medicine Co., Ltd. | Sponsor R \& D Strategy Adjustment | Sponsor / business decision |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Oct 18, 2023source: clinicaltrials